Remepy Reports Strong Clinical Phase IIa Results for Hybridopa, a First‑in‑Class Hybrid Drug for Parkinson’s Disease
Remepy has reported strong results from a Phase IIa clinical trial of Hybridopa, a first‑in‑class hybrid drug for Parkinson’s disease.
Hybridopa combines immediate‑release levodopa/carbidopa with a digital protocol delivered via the DopApp mobile application, using adaptive, personalized protocols to enhance motor and non‑motor outcomes.
The randomized, double‑blind, placebo‑controlled Phase IIa study (N=41) showed a mean reduction of 9.7 points on the MDS‑UPDRS Parts I+II+III in the Hybridopa arm versus 1.95 points in the control, with high responder rates and objective neuroimaging evidence of improved brain connectivity in motor and limbic circuits.
The data support progression to a global Phase III trial and position Hybridopa as one of the most advanced drug‑software combination programs in Parkinson’s disease.
Sources:
Remepy Reports Strong Clinical Phase IIa Results for Hybridopa ...
Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market
Remepy Launches with $15 Million in Funding To Bring First Hybrid ...
Remepy Reports Strong Clinical Phase IIa Results for Hybridopa
Merck KGaA, Remepy team up on hybrid drugs for rare tumors
Remepy's hybrid Parkinson's therapy poised for phase 3
Digital Therapeutics for Parkinson's Disease: The Hybrid Drug Approach - Remepy
The drug that thinks AND comes with an app!